Resources
Events
All Resources
DNA sequencing became one of the steepest cost declines in the history of technology, and a single company captured the majority of the value. Reading a protein the way we now read a gene is the harder problem; with it comes a large prize, and up-and-coming platforms are vying for it.
DNA sequencing became one of the steepest cost declines in the history of technology, and a single company captured the majority of the value. Reading a protein the way we now read a gene is the harder problem; with it comes a large prize, and up-and-coming platforms are vying for it.
Why a fund investing in non-pharma biotech approaches bioethics differently, and the framework we use to practice it.
Why a fund investing in non-pharma biotech approaches bioethics differently, and the framework we use to practice it.
Why the next generation of fund-returners will be category kings, and why biology is where they're being built
Why the next generation of fund-returners will be category kings, and why biology is where they're being built
Part 1: Bending the Cost Curve
Part 1: Bending the Cost Curve
The Methane Economy
The Methane Economy
From evolutionary constraint to competitive advantage.
From evolutionary constraint to competitive advantage.
.png)
Lessons from biotech’s first breakout moment.
Lessons from biotech’s first breakout moment.
.png)
Our bioindustrial advantage is vulnerable. Here’s how we secure it.
Our bioindustrial advantage is vulnerable. Here’s how we secure it.
.png)
How biotech in space will improve life on Earth.
How biotech in space will improve life on Earth.
.jpg)
How to diversify your capital stack and reduce dilution.
How to diversify your capital stack and reduce dilution.
A peek behind the curtain.
A peek behind the curtain.
.jpg)
Your search returned no results. Try adjusting your search.